BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernandez-García T, Candia R, Bruce MG, Rabkin CS. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol. 2014;109:485-495. [PMID: 24589670 DOI: 10.1038/ajg.2014.24] [Cited by in Crossref: 95] [Cited by in F6Publishing: 80] [Article Influence: 13.6] [Reference Citation Analysis]
Number Citing Articles
1 Mawad AMM, Hesham AE, Khan S, Nawab J. The Role of Fungi and Genes for the Removal of Environmental Contaminants from Water/Wastewater Treatment Plants. In: Hesham AE, Upadhyay RS, Sharma GD, Manoharachary C, Gupta VK, editors. Fungal Biotechnology and Bioengineering. Cham: Springer International Publishing; 2020. pp. 349-70. [DOI: 10.1007/978-3-030-41870-0_15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Camorlinga-Ponce M, Gómez-Delgado A, Aguilar-Zamora E, Torres RC, Giono-Cerezo S, Escobar-Ogaz A, Torres J. Phenotypic and Genotypic Antibiotic Resistance Patterns in Helicobacter pylori Strains From Ethnically Diverse Population in México. Front Cell Infect Microbiol 2020;10:539115. [PMID: 33643927 DOI: 10.3389/fcimb.2020.539115] [Reference Citation Analysis]
3 Carrillo-Larco RM, Anza-Ramírez C, Saal-Zapata G, Villarreal-Zegarra D, Zafra-Tanaka JH, Ugarte-Gil C, Bernabé-Ortiz A. Type 2 diabetes mellitus and antibiotic-resistant infections: a systematic review and meta-analysis. J Epidemiol Community Health 2021:jech-2020-216029. [PMID: 34326183 DOI: 10.1136/jech-2020-216029] [Reference Citation Analysis]
4 Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19:1637-1650. [PMID: 26245678 DOI: 10.1517/14728222.2015.1073261] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
5 Liou JM, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Wu JY, Luo JC, Liou TC, Chang WH, Tseng CH, Wu CY, Yang TH, Chang CC, Wang HP, Sheu BS, Lin JT, Bair MJ, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study. PLoS One. 2015;10:e0124199. [PMID: 25942450 DOI: 10.1371/journal.pone.0124199] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 9.8] [Reference Citation Analysis]
6 Ortiz V, Estevez-Ordonez D, Montalvan-Sanchez E, Urrutia-Argueta S, Israel D, Krishna US, Romero-Gallo J, Wilson KT, Peek RM, Dominguez R, Morgan DR. Helicobacter pylori antimicrobial resistance and antibiotic consumption in the low-resource Central America setting. Helicobacter 2019;24:e12595. [PMID: 31111610 DOI: 10.1111/hel.12595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Zhang S, Lee DS, Morrissey R, Aponte-Pieras JR, Rogers AB, Moss SF. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. Cancer Lett 2014;355:106-12. [PMID: 25218349 DOI: 10.1016/j.canlet.2014.09.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
8 Matta AJ, Zambrano DC, Pazos AJ. Punctual mutations in 23S rRNA gene of clarithromycin-resistant Helicobacter pylori in Colombian populations. World J Gastroenterol 2018; 24(14): 1531-1539 [PMID: 29662291 DOI: 10.3748/wjg.v24.i14.1531] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
9 Arama SS, Tiliscan C, Negoita C, Croitoru A, Arama V, Mihai CM, Pop F, Garg A. Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients. Gastroenterol Res Pract 2016;2016:5061640. [PMID: 26858750 DOI: 10.1155/2016/5061640] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
10 Doorakkers E, Lagergren J, Gajulapuri VK, Callens S, Engstrand L, Brusselaers N. Helicobacter pylori eradication in the Swedish population. Scandinavian Journal of Gastroenterology 2017;52:678-85. [DOI: 10.1080/00365521.2017.1303844] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
11 Dacoll C, Sánchez-delgado J, Balter H, Pazos X, Di Pace M, Sandoya G, Cohen H, Calvet X. An optimized clarithromycin-free 14-day triple therapy for Helicobacter pylori eradication achieves high cure rates in Uruguay. Gastroenterología y Hepatología 2017;40:447-54. [DOI: 10.1016/j.gastrohep.2017.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155: 1372-1382. e17. [PMID: 29990487 DOI: 10.1053/j.gastro.2018.07.007] [Cited by in Crossref: 274] [Cited by in F6Publishing: 238] [Article Influence: 91.3] [Reference Citation Analysis]
13 Asif MB, Hai FI, Singh L, Price WE, Nghiem LD. Degradation of Pharmaceuticals and Personal Care Products by White-Rot Fungi—a Critical Review. Curr Pollution Rep 2017;3:88-103. [DOI: 10.1007/s40726-017-0049-5] [Cited by in Crossref: 67] [Cited by in F6Publishing: 36] [Article Influence: 16.8] [Reference Citation Analysis]
14 Guo B, Cao NW, Zhou HY, Chu XJ, Li BZ. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis. Microb Pathog 2021;152:104661. [PMID: 33249167 DOI: 10.1016/j.micpath.2020.104661] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Lin TF, Hsu PI. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J Gastroenterol 2018; 24(40): 4548-4553 [PMID: 30386104 DOI: 10.3748/wjg.v24.i40.4548] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
16 Van Giau V, An SSA, Hulme J. Recent advances in the treatment of pathogenic infections using antibiotics and nano-drug delivery vehicles. Drug Des Devel Ther 2019;13:327-43. [PMID: 30705582 DOI: 10.2147/DDDT.S190577] [Cited by in Crossref: 45] [Cited by in F6Publishing: 17] [Article Influence: 22.5] [Reference Citation Analysis]
17 Liou JM, Chen PY, Kuo YT, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Toward population specific and personalized treatment of Helicobacter pylori infection. J Biomed Sci 2018;25:70. [PMID: 30285834 DOI: 10.1186/s12929-018-0471-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
18 Gaálová J, Bourassi M, Soukup K, Trávníčková T, Bouša D, Sundararajan S, Losada O, Kasher R, Friess K, Sofer Z. Modified Single-Walled Carbon Nanotube Membranes for the Elimination of Antibiotics from Water. Membranes (Basel) 2021;11:720. [PMID: 34564537 DOI: 10.3390/membranes11090720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Lee JW, Kim N, Nam RH, Lee SM, Kwon YH, Sohn SD, Kim JM, Lee DH, Jung HC. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance. Helicobacter. 2019;24:e12561. [PMID: 30632237 DOI: 10.1111/hel.12561] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 14.5] [Reference Citation Analysis]
20 马春婷, 高峰. 幽门螺杆菌对甲硝唑耐药机制的研究进展. 世界华人消化杂志 2014; 22(16): 2271-2276 [DOI: 10.11569/wcjd.v22.i16.2271] [Reference Citation Analysis]
21 Liou JM, Bair MJ, Chen CC, Lee YC, Chen MJ, Chen CC, Tseng CH, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Chang WH, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hung HW, Lin JT, Chang CY, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial. Am J Gastroenterol. 2016;111:381-387. [PMID: 26832653 DOI: 10.1038/ajg.2015.439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
22 Salas-jara MJ, Sanhueza EA, Retamal-díaz A, González C, Urrutia H, García A. Probiotic Lactobacillus fermentum UCO-979C biofilm formation on AGS and Caco-2 cells and Helicobacter pylori inhibition. Biofouling 2016;32:1245-57. [DOI: 10.1080/08927014.2016.1249367] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
23 Cano-Contreras AD, Rascón O, Amieva-Balmori M, Ríos-Gálvez S, Maza YJ, Meixueiro-Daza A, Roesch-Dietlen F, Remes-Troche JM. Approach, attitudes, and knowledge of general practitioners in relation to Helicobacter pylori is inadequate. There is much room for improvement! Rev Gastroenterol Mex (Engl Ed) 2018;83:16-24. [PMID: 28385468 DOI: 10.1016/j.rgmx.2017.02.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
24 Boehnke KF, Valdivieso M, Bussalleu A, Sexton R, Thompson KC, Osorio S, Novoa Reyes I, Crowley JJ, Baker LH, Xi C. Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru. Infect Drug Resist 2017;10:85-90. [PMID: 28331349 DOI: 10.2147/IDR.S123798] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
25 O’Connor A, Vaira D, Gisbert JP, O’Morain C. Treatment of Helicobacter pylori infection 2014. Helicobacter. 2014;19 Suppl 1:38-45. [PMID: 25167944 DOI: 10.1111/hel.12163] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
26 Mei H, Tu H. Vitamin C and Helicobacter pylori Infection: Current Knowledge and Future Prospects. Front Physiol 2018;9:1103. [PMID: 30154733 DOI: 10.3389/fphys.2018.01103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
27 Kasahun GG, Demoz GT, Desta DM. Primary Resistance Pattern of Helicobacter pylori to Antibiotics in Adult Population: A Systematic Review. Infect Drug Resist 2020;13:1567-73. [PMID: 32547126 DOI: 10.2147/IDR.S250200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
28 Bosques-Padilla FJ, Remes-Troche JM, González-Huezo MS, Pérez-Pérez G, Torres-López J, Abdo-Francis JM, Bielsa-Fernandez MV, Camargo MC, Esquivel-Ayanegui F, Garza-González E, Hernández-Guerrero AI, Herrera-Goepfert R, Huerta-Iga FM, Leal-Herrera Y, Lopéz-Colombo A, Ortiz-Olvera NX, Riquelme-Pérez A, Sampieri CL, Uscanga-Domínguez LF, Velarde-Ruiz Velasco JA. The fourth Mexican consensus on Helicobacter pylori. Rev Gastroenterol Mex (Engl Ed) 2018;83:325-41. [PMID: 29941237 DOI: 10.1016/j.rgmx.2018.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
29 Kuo YT, Liou JM, El-Omar EM, Wu JY, Leow AHR, Goh KL, Das R, Lu H, Lin JT, Tu YK. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:707-715. [PMID: 28781119 DOI: 10.1016/s2468-1253(17)30219-4] [Cited by in Crossref: 96] [Cited by in F6Publishing: 39] [Article Influence: 24.0] [Reference Citation Analysis]
30 Amar N, Peretz A, Gerchman Y. A cheap, simple high throughput method for screening native Helicobacter pylori urease inhibitors using a recombinant Escherichia coli , its validation and demonstration of Pistacia atlantica methanolic extract effectivity and specificity. Journal of Microbiological Methods 2017;133:40-5. [DOI: 10.1016/j.mimet.2016.11.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Miftahussurur M, Cruz M, Subsomwong P, Jiménez Abreu JA, Hosking C, Nagashima H, Akada J, Yamaoka Y. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic. Am J Trop Med Hyg 2017;96:1050-9. [PMID: 28193745 DOI: 10.4269/ajtmh.16-0729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
32 Rollan A, Arab JP, Camargo MC, Candia R, Harris P, Ferreccio C, Rabkin CS, Gana JC, Cortés P, Herrero R, Durán L, García A, Toledo C, Espino A, Lustig N, Sarfatis A, Figueroa C, Torres J, Riquelme A. Management of Helicobacter pylori infection in Latin America: A Delphi technique-based consensus. World J Gastroenterol 2014; 20(31): 10969-10983 [PMID: 25152601 DOI: 10.3748/wjg.v20.i31.10969] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
33 Pietroiusti A, Magrini A, Campagnolo L. New frontiers in nanotoxicology: Gut microbiota/microbiome-mediated effects of engineered nanomaterials. Toxicology and Applied Pharmacology 2016;299:90-5. [DOI: 10.1016/j.taap.2015.12.017] [Cited by in Crossref: 94] [Cited by in F6Publishing: 75] [Article Influence: 18.8] [Reference Citation Analysis]
34 Oporto M, Pavez M, Troncoso C, Cerda A, Hofmann E, Sierralta A, Rios E, Coppelli L, Barrientos L. Prevalence of Infection and Antibiotic Susceptibility of Helicobacter pylori: An Evaluation in Public and Private Health Systems of Southern Chile. Pathogens 2019;8:E226. [PMID: 31717523 DOI: 10.3390/pathogens8040226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Rosero YL, Arévalo-jaimes BV, Delgado MP, Vera-chamorro JF, García D, Ramírez A, Rodriguez-urrego PA, Álvarez J, Jaramillo CA. Evaluation of Helicobacter pylori Infection and Clarithromycin Resistance in Strains From Symptomatic Colombian Children. Journal of Pediatric Gastroenterology & Nutrition 2018;67:601-4. [DOI: 10.1097/mpg.0000000000002016] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos MDCF, Zaterka S, Assumpção PP, Barbosa AJA, Barbuti R, Braga LL, Breyer H, Carvalhaes A, Chinzon D, Cury M, Domingues G, Jorge JL, Maguilnik I, Marinho FP, Moraes-filho JPD, Parente JML, Paula-e-silva CMD, Pedrazzoli-júnior J, Ramos AFP, Seidler H, Spinelli JN, Zir JV. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arq Gastroenterol 2018;55:97-121. [DOI: 10.1590/s0004-2803.201800000-20] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
37 Miftahussurur M, Cruz M, Doohan D, Subsomwong P, Abreu JAJ, Hosking C, Waskito LA, Yamaoka Y. Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic. PLoS One 2019;14:e0213868. [PMID: 30917150 DOI: 10.1371/journal.pone.0213868] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
38 Li XX, Shi S, Rong L, Feng MQ, Zhong L. The impact of liposomal linolenic acid on gastrointestinal microbiota in mice. Int J Nanomedicine 2018;13:1399-409. [PMID: 29563795 DOI: 10.2147/IJN.S151825] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
39 Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112:212-239. [PMID: 28071659 DOI: 10.1038/ajg.2016.563] [Cited by in Crossref: 515] [Cited by in F6Publishing: 412] [Article Influence: 128.8] [Reference Citation Analysis]
40 Taheran M, Naghdi M, Brar SK, Verma M, Surampalli R. Emerging contaminants: Here today, there tomorrow! Environmental Nanotechnology, Monitoring & Management 2018;10:122-6. [DOI: 10.1016/j.enmm.2018.05.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 9.7] [Reference Citation Analysis]
41 García A, Navarro K, Sanhueza E, Pineda S, Pastene E, Quezada M, Henríquez K, Karlyshev A, Villena J, González C. Characterization of Lactobacillus fermentum UCO-979C, a probiotic strain with a potent anti-Helicobacter pylori activity. Electronic Journal of Biotechnology 2017;25:75-83. [DOI: 10.1016/j.ejbt.2016.11.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
42 Mansour-Ghanaei F, Pedarpour Z, Shafaghi A, Joukar F. Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens for Helicobacter Pylori Infection Eradication. Middle East J Dig Dis. 2017;9:100-106. [PMID: 28638586 DOI: 10.15171/mejdd.2017.58] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
43 Niederman R, Feres M, Ogunbodede E. Dentistry. In: Debas HT, Donkor P, Gawande A, Jamison DT, Kruk ME, Mock CN, editors. Disease Control Priorities, Third Edition (Volume 1): Essential Surgery. The World Bank; 2015. pp. 173-95. [DOI: 10.1596/978-1-4648-0346-8_ch10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Damke PP, Dhanaraju R, Marsin S, Radicella JP, Rao DN. The nuclease activities of both the Smr domain and an additional LDLK motif are required for an efficient anti-recombination function of Helicobacter pylori MutS2. Mol Microbiol 2015;96:1240-56. [PMID: 25800579 DOI: 10.1111/mmi.13003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
45 O'Connor A, Gisbert JP, O'Morain C, Ladas S. Treatment of Helicobacter pylori Infection 2015. Helicobacter. 2015;20 Suppl 1:54-61. [PMID: 26372826 DOI: 10.1111/hel.12258] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
46 Fiorini G, Saracino IM, Zullo A, Gatta L, Pavoni M, Vaira D. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains. Helicobacter 2017;22:e12448. [DOI: 10.1111/hel.12448] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
47 Caliskan R, Tokman HB, Erzin Y, Saribas S, Yuksel P, Bolek BK, Sevuk EO, Demirci M, Yılmazli O, Akgul O, Kalayci F, Cakan H, Salih B, Bal K, Kocazeybek B. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop 2015;48:278-84. [PMID: 26108005 DOI: 10.1590/0037-8682-0027-2015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
48 Escandón RA, del Campo M, López-solis R, Obreque-slier E, Toledo H. Antibacterial effect of kaempferol and (−)-epicatechin on Helicobacter pylori. Eur Food Res Technol 2016;242:1495-502. [DOI: 10.1007/s00217-016-2650-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
49 Mannion A, Dzink-Fox J, Shen Z, Piazuelo MB, Wilson KT, Correa P, Peek RM Jr, Camargo MC, Fox JG. Helicobacter pylori Antimicrobial Resistance and Gene Variants in High- and Low-Gastric-Cancer-Risk Populations. J Clin Microbiol 2021;59:e03203-20. [PMID: 33692136 DOI: 10.1128/JCM.03203-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Zhang S, Lee DS, Morrissey R, Aponte-Pieras JR, Rogers AB, Moss SF. Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. Cancer Lett. 2015;359:345-351. [PMID: 25853150 DOI: 10.1016/j.canlet.2015.01.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
51 Rogers BB, Gold BD. Helicobacter pylori Gastritis: Susceptible to Further Testing? Dig Dis Sci 2016;61:2156-9. [PMID: 27234271 DOI: 10.1007/s10620-016-4200-8] [Reference Citation Analysis]
52 Arenas A, Serrano C, Quiñones L, Harris P, Sandoval M, Lavanderos M, Sepúlveda R, Maquilón S, Echeverría A, Ríos C, Fuentes-López E, Rojas L, Jorquera A, Pizarro M, Camargo MC, Riquelme A. High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis. Sci Rep 2019;9:20070. [PMID: 31882676 DOI: 10.1038/s41598-019-56399-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
53 Gold BD. Resistance testing for Helicobacter pylori infection: is it finally ready for prime time? J Pediatr Gastroenterol Nutr 2014;59:3-4. [PMID: 25222802 DOI: 10.1097/MPG.0000000000000438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
54 Kuo SH, Yeh KH, Wu MS, Lin CW, Wei MF, Liou JM, Wang HP, Chen LT, Cheng AL. First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. Sci Rep 2017;7:14333. [PMID: 29084984 DOI: 10.1038/s41598-017-14102-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
55 Martins GM, Sanches BS, Moretzsohn LD, Lima KS, Cota BD, Coelho LG. Molecular detection of clarithromycin and fluoroquinolones resistance in Helicobacter pylori infection, directly applied to gastric biopsies, in an urban brazilian population. Arq Gastroenterol. 2016;53:113-117. [PMID: 27305419 DOI: 10.1590/s0004-28032016000200012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
56 Ladrón-de-Guevara L, Bornstein-Quevedo L, González-Huezo S, Castañeda-Romero B, Costa FG, di Silvio-López M. Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: Results from an open-label, randomized, noninferiority phase iiib trial. Rev Gastroenterol Mex (Engl Ed) 2019;84:274-83. [PMID: 30060902 DOI: 10.1016/j.rgmx.2018.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Lucio-Sauceda DG, Urrutia-Baca VH, Gomez-Flores R, De La Garza-Ramos MA, Tamez-Guerra P, Orozco-Flores A. Antimicrobial and Anti-Biofilm Effect of an Electrolyzed Superoxidized Solution at Neutral-pH against Helicobacter pylori. Biomed Res Int 2019;2019:6154867. [PMID: 31930132 DOI: 10.1155/2019/6154867] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang TD, Hoebeke M, Bénéjat L, Lehours P, Goossens H, Glupczynski Y; European Helicobacter pylori Antimicrobial Susceptibility Testing Working Group. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut 2021:gutjnl-2021-324032. [PMID: 33837118 DOI: 10.1136/gutjnl-2021-324032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
59 Parra-Sepúlveda C, Merino JS, Sáez-Carrillo K, González C, García-Cancino A. ANTIBIOTIC RESISTANCE SURVEILLANCE OF HELICOBACTER PYLORI AT THE BIOBÍO REGION (CHILE) IN A DECADE. Arq Gastroenterol 2019;56:361-6. [PMID: 31721972 DOI: 10.1590/S0004-2803.201900000-72] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
60 Sierra MS, Cueva P, Bravo LE, Forman D. Stomach cancer burden in Central and South America. Cancer Epidemiol. 2016;44 Suppl 1:S62-S73. [PMID: 27678324 DOI: 10.1016/j.canep.2016.03.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
61 Liou JM, Chen CC, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Liou TC, Chang WH, Hsu YC, Tseng CH, Chang CC, Bair MJ, Liu TY, Hsieh CF, Tsao FY, Shun CT, Lin JT, Lee YC, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial. Gut 2016;65:1784-92. [PMID: 26338825 DOI: 10.1136/gutjnl-2015-310142] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 7.7] [Reference Citation Analysis]
62 Mosites E, Bruden D, Morris J, Reasonover A, Rudolph K, Hurlburt D, Hennessy T, McMahon B, Bruce M. Antimicrobial resistance among Helicobacter pylori isolates in Alaska, 2000-2016. J Glob Antimicrob Resist 2018;15:148-53. [PMID: 29969753 DOI: 10.1016/j.jgar.2018.06.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
63 Chen M, Wu M, Chen C, Chen C, Fang Y, Bair M, Chang C, Lee J, Hsu W, Luo J, Lin J, Liou J; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. Journal of Antimicrobial Chemotherapy 2017;72:3481-9. [DOI: 10.1093/jac/dkx320] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
64 Zerbetto De Palma G, Mendiondo N, Wonaga A, Viola L, Ibarra D, Campitelli E, Salim N, Corti R, Goldman C, Catalano M. Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City. Microb Drug Resist 2017;23:351-8. [PMID: 27391421 DOI: 10.1089/mdr.2015.0361] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
65 Eshraghian A. Epidemiology of Helicobacter pylori infection among the healthy population in Iran and countries of the Eastern Mediterranean Region: A systematic review of prevalence and risk factors. World J Gastroenterol 2014; 20(46): 17618-17625 [PMID: 25516677 DOI: 10.3748/wjg.v20.i46.17618] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 40] [Article Influence: 7.1] [Reference Citation Analysis]
66 Muñoz AB, Stepanian J, Trespalacios AA, Vale FF. Bacteriophages of Helicobacter pylori. Front Microbiol 2020;11:549084. [PMID: 33281754 DOI: 10.3389/fmicb.2020.549084] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
67 Corral JE, Mera R, Dye CW, Morgan DR. Helicobacter pylori recurrence after eradication in Latin America: Implications for gastric cancer prevention. World J Gastrointest Oncol 2017; 9(4): 184-193 [PMID: 28451066 DOI: 10.4251/wjgo.v9.i4.184] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
68 Molina MC, Bautista LF, Catalá M, de las Heras MR, Martínez-hidalgo P, San-sebastián J, González-benítez N. From Laboratory Tests to the Ecoremedial System: The Importance of Microorganisms in the Recovery of PPCPs-Disturbed Ecosystems. Applied Sciences 2020;10:3391. [DOI: 10.3390/app10103391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
69 Baroni MR, Bucci P, Giani RN, Giusti A, Tedeschi FA, Salvatierra E, Barbaglia Y, Jimenez F, Zalazar FE. Usefulness of rapid urease test samples for molecular analysis of clarithromycin resistance in Helicobacter pylori. Revista Argentina de Microbiología 2018;50:359-64. [DOI: 10.1016/j.ram.2017.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
70 Contreras M, Benejat L, Mujica H, Peña J, García-amado M, Michelangeli F, Lehours P. Real-time PCR detection of a 16S rRNA single mutation of Helicobacter pylori isolates associated with reduced susceptibility and resistance to tetracycline in the gastroesophageal mucosa of individual hosts. Journal of Medical Microbiology 2019;68:1287-91. [DOI: 10.1099/jmm.0.001051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Zafra-Tanaka JH, Tenorio-Mucha J, Villarreal-Zegarra D, Carrillo-Larco R, Bernabe-Ortiz A. Cancer-related mortality in Peru: Trends from 2003 to 2016. PLoS One 2020;15:e0228867. [PMID: 32027719 DOI: 10.1371/journal.pone.0228867] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
72 Obaidat MM, Roess AA. First nationwide seroepidemiology and risk factors report of Helicobater pylori in Jordan. Helicobacter 2019;24:e12572. [PMID: 30868689 DOI: 10.1111/hel.12572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? Therap Adv Gastroenterol. 2020;13:1756284820968736. [PMID: 33240392 DOI: 10.1177/1756284820968736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
74 Fahey JW, Stephenson KK, Wallace AJ. Dietary amelioration of Helicobacter infection. Nutr Res 2015;35:461-73. [PMID: 25799054 DOI: 10.1016/j.nutres.2015.03.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
75 Trespalacios-Rangél AA, Otero W, Arévalo-Galvis A, Poutou-Piñales RA, Rimbara E, Graham DY. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014). PLoS One 2016;11:e0160007. [PMID: 27454429 DOI: 10.1371/journal.pone.0160007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
76 Zhang J, Han C, Lu WQ, Wang N, Wu SR, Wang YX, Ma JP, Wang JH, Hao C, Yuan DH, Liu N, Shi YQ. A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment. J Dig Dis 2020;21:256-63. [PMID: 32348007 DOI: 10.1111/1751-2980.12870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
77 Iwańczak B, Francavailla R. Helicobacter pylori infection in pediatrics. Helicobacter 2014;19 Suppl 1:46-51. [PMID: 25167945 DOI: 10.1111/hel.12158] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
78 Serrano CA, Leon MA, Palma C, Vera M, Hernandez C, Harris PR. Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country. Journal of Pediatric Gastroenterology & Nutrition 2017;64:e56-60. [DOI: 10.1097/mpg.0000000000001257] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
79 Hu Y, Zhu Y, Lu NH. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Front Cell Infect Microbiol 2017;7:168. [PMID: 28529929 DOI: 10.3389/fcimb.2017.00168] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
80 Gatta L, Scarpignato C, Fiorini G, Belsey J, Saracino IM, Ricci C, Vaira D. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther 2018;47:1261-9. [DOI: 10.1111/apt.14597] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 9.7] [Reference Citation Analysis]